Beranda › Leukemia Mieloid Akut › Michigan

Uji klinis Leukemia Mieloid Akut di Michigan

24 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi di Michigan.

Kota di Michigan

Teks studi resmi (Bahasa Inggris)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
dan 3 lainnya

Menerima pesertaFase 2

Usia 60 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
dan 68 lainnya

Menerima pesertaStudi observasionalSukarelawan sehat diterima

Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
dan 6 lainnya

Menerima pesertaFase 2

Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Henry Ford Health System, Detroit
Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
dan 14 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor

Menerima pesertaFase 1

Hingga usia 21 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
dan 6 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
dan 11 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
dan 9 lainnya

Menerima pesertaFase 2

Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo
dan 1 lainnya

Menerima pesertaFase 3

6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

START Midwest, Grand Rapids

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo

Menerima pesertaFase 3

Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
dan 2 lainnya

Menerima pesertaFase 1/2

Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

C.S. Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit

Menerima pesertaFase 3

29 Days – 21 Years · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Michigan, Ann Arbor
Wayne State University School of Medicine, Detroit

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Karmanos Cancer Institute, Detroit
Henry Ford Cancer Institute, Detroit

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

START Midwest, Grand Rapids

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT07751991

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Henry Ford Cancer Institute, Detroit

Menerima pesertaFase 3

Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Jul 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of Michigan, Ann Arbor
Children's Hospital of Michigan, Detroit
Henry Ford Health System, Detroit
dan 2 lainnya

Menerima pesertaStudi observasional

Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

University of Michigan, Ann Arbor

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT05768932

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mei 2026 · NCT02269592

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Karmanos Cancer Institute, Detroit

Menerima pesertaFase 2

Usia 18 hingga 66 · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT05735184

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

Menerima pesertaStudi observasional

Usia 12 hingga 80 · Semua jenis kelamin · Diperbarui 28 Agu 2025 · NCT07145411

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.